<DOC>
	<DOCNO>NCT00839163</DOCNO>
	<brief_summary>The purpose study compare safety efficacy BAY59-7939 safety efficacy license drug enoxaparin license oral vitamin K-antagonist find optimal dose BAY59-7939 anticipated phase III trial future clinical use .</brief_summary>
	<brief_title>Oral Direct Factor Xa Inhibitor BAY59-7939 Patients With Acute Symptomatic Proximal Deep Vein Thrombosis ( ODIXa-DVT )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Patients acute symptomatic proximal deep vein thrombosis Contraindication comparator drug Symptomatic Pulmonary embolism Conditions increase bleed risk Unstable patient reduce life expectancy Severe renal impairment Impaired liver function Strong CYP 3A4 inhibitor Platelet aggregation inhibitor ( exception : ASA 500mg ) therapy anticoagulant fibrinolytics NSAIDs halflife &gt; 17 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Embolism Thrombosis</keyword>
	<keyword>Pulmonary embolism</keyword>
	<keyword>Embolism</keyword>
	<keyword>Thrombosis</keyword>
</DOC>